{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-257423","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2026-06-04T20:15:16+00:00","discovered_at":"2026-06-04T20:17:00.227710+00:00","generated_at":"2026-06-04T20:47:17.053351+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Stockholders approve amended 2024 equity plan with 3.23M share increase and modified evergreen provision","bullets":["Shareholders approved one-time increase of 3,231,638 shares (approx. 8% of outstanding) to the 2024 Equity Incentive Plan.","Annual evergreen provision amended: fixed cap of 2,407,100 shares removed; future annual increase set at 5% of outstanding shares beginning FY2027.","Directors R. Michael Carruthers, Valerie M. Jansen, and Edward T. Mathers elected as Class II directors until 2029.","Shareholders ratified KPMG LLP as independent auditor for fiscal year ending Dec. 31, 2026.","Incentive stock option limit under plan set at 8 million shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-257423","json":"https://secwatch.observer/filing/0001193125-26-257423.json","markdown":"https://secwatch.observer/filing/0001193125-26-257423.md","text":"https://secwatch.observer/filing/0001193125-26-257423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/okur-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:47:17.053351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e209a4ce9e3893a215b1ac28ee3975b912839a9","claim":"OnKure Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2024 Equity Incentive Plan at the 2026-06-03 meeting.","evidence_excerpt":"For Against Abstentions Broker Non-Votes 16,431,575 3,490,523 1,895 5,466,123","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"9470e1749a6628222606e3b2d16d4d62ff9fe291","claim":"OnKure Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-03 meeting.","evidence_excerpt":"R. Michael Carruthers 19,776,757 147,236 5,466,123 Valerie M. Jansen, M.D., Ph.D. 17,796,919 2,127,074 5,466,123 Edward T. Mathers 19,855,396 68,597 5,466,123","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"c465393df7423dab99448b2a323ca2faf12ef6ec","claim":"OnKure Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm at the 2026-06-03 meeting.","evidence_excerpt":"For Against Abstentions Broker Non-Votes 25,329,425 60,370 321 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}